Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
Abstract Immunotherapy for cancer is a rapidly developing treatment that modifies the immune system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 family that plays an immunoregulatory role in the T cell response, has been highlighted as a novel potential target for ca...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-10-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-022-01364-7 |
| _version_ | 1811335069196877824 |
|---|---|
| author | Binghao Zhao Huanzhang Li Yu Xia Yaning Wang Yuekun Wang Yixin Shi Hao Xing Tian Qu Yu Wang Wenbin Ma |
| author_facet | Binghao Zhao Huanzhang Li Yu Xia Yaning Wang Yuekun Wang Yixin Shi Hao Xing Tian Qu Yu Wang Wenbin Ma |
| author_sort | Binghao Zhao |
| collection | DOAJ |
| description | Abstract Immunotherapy for cancer is a rapidly developing treatment that modifies the immune system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 family that plays an immunoregulatory role in the T cell response, has been highlighted as a novel potential target for cancer immunotherapy. B7-H3 has been shown to play an inhibitory role in T cell activation and proliferation, participate in tumor immune evasion and influence both the immune response and tumor behavior through different signaling pathways. B7-H3 expression has been found to be aberrantly upregulated in many different cancer types, and an association between B7-H3 expression and poor prognosis has been established. Immunotherapy targeting B7-H3 through different approaches has been developing rapidly, and many ongoing clinical trials are exploring the safety and efficacy profiles of these therapies in cancer. In this review, we summarize the emerging research on the function and underlying pathways of B7-H3, the expression and roles of B7-H3 in different cancer types, and the advances in B7-H3-targeted therapy. Considering different tumor microenvironment characteristics and results from preclinical models to clinical practice, the research indicates that B7-H3 is a promising target for future immunotherapy, which might eventually contribute to an improvement in cancer immunotherapy that will benefit patients. |
| first_indexed | 2024-04-13T17:18:33Z |
| format | Article |
| id | doaj.art-70bc0c98887748f3883dd05913373de4 |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-04-13T17:18:33Z |
| publishDate | 2022-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-70bc0c98887748f3883dd05913373de42022-12-22T02:38:04ZengBMCJournal of Hematology & Oncology1756-87222022-10-0115113110.1186/s13045-022-01364-7Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapyBinghao Zhao0Huanzhang Li1Yu Xia2Yaning Wang3Yuekun Wang4Yixin Shi5Hao Xing6Tian Qu7Yu Wang8Wenbin Ma9Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Immunotherapy for cancer is a rapidly developing treatment that modifies the immune system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 family that plays an immunoregulatory role in the T cell response, has been highlighted as a novel potential target for cancer immunotherapy. B7-H3 has been shown to play an inhibitory role in T cell activation and proliferation, participate in tumor immune evasion and influence both the immune response and tumor behavior through different signaling pathways. B7-H3 expression has been found to be aberrantly upregulated in many different cancer types, and an association between B7-H3 expression and poor prognosis has been established. Immunotherapy targeting B7-H3 through different approaches has been developing rapidly, and many ongoing clinical trials are exploring the safety and efficacy profiles of these therapies in cancer. In this review, we summarize the emerging research on the function and underlying pathways of B7-H3, the expression and roles of B7-H3 in different cancer types, and the advances in B7-H3-targeted therapy. Considering different tumor microenvironment characteristics and results from preclinical models to clinical practice, the research indicates that B7-H3 is a promising target for future immunotherapy, which might eventually contribute to an improvement in cancer immunotherapy that will benefit patients.https://doi.org/10.1186/s13045-022-01364-7B7-H3Tumor microenvironmentCancer immune checkpointsCancer immunotherapyBiomarker |
| spellingShingle | Binghao Zhao Huanzhang Li Yu Xia Yaning Wang Yuekun Wang Yixin Shi Hao Xing Tian Qu Yu Wang Wenbin Ma Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy Journal of Hematology & Oncology B7-H3 Tumor microenvironment Cancer immune checkpoints Cancer immunotherapy Biomarker |
| title | Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy |
| title_full | Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy |
| title_fullStr | Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy |
| title_full_unstemmed | Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy |
| title_short | Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy |
| title_sort | immune checkpoint of b7 h3 in cancer from immunology to clinical immunotherapy |
| topic | B7-H3 Tumor microenvironment Cancer immune checkpoints Cancer immunotherapy Biomarker |
| url | https://doi.org/10.1186/s13045-022-01364-7 |
| work_keys_str_mv | AT binghaozhao immunecheckpointofb7h3incancerfromimmunologytoclinicalimmunotherapy AT huanzhangli immunecheckpointofb7h3incancerfromimmunologytoclinicalimmunotherapy AT yuxia immunecheckpointofb7h3incancerfromimmunologytoclinicalimmunotherapy AT yaningwang immunecheckpointofb7h3incancerfromimmunologytoclinicalimmunotherapy AT yuekunwang immunecheckpointofb7h3incancerfromimmunologytoclinicalimmunotherapy AT yixinshi immunecheckpointofb7h3incancerfromimmunologytoclinicalimmunotherapy AT haoxing immunecheckpointofb7h3incancerfromimmunologytoclinicalimmunotherapy AT tianqu immunecheckpointofb7h3incancerfromimmunologytoclinicalimmunotherapy AT yuwang immunecheckpointofb7h3incancerfromimmunologytoclinicalimmunotherapy AT wenbinma immunecheckpointofb7h3incancerfromimmunologytoclinicalimmunotherapy |